Core Viewpoint - The announcement details the planned share transfer of 4,229,388 shares, representing 3.00% of the total share capital of Shanghai Yinos Technology Co., Ltd. (益诺思), by Shanghai Zhangjiang Biopharmaceutical Base Development Co., Ltd. (张江生药基地) to institutional investors through a pricing inquiry transfer method [3][9]. Group 1: Share Transfer Details - The total number of shares to be transferred is 4,229,388, which accounts for 3.00% of Yinos's total share capital as of October 31, 2025 [3][9]. - The transfer will not occur through centralized bidding or block trading, and the shares acquired through this transfer cannot be transferred within six months [3][9]. - The transfer is motivated by the seller's need for funds [9]. Group 2: Seller Information - The seller, Shanghai Zhangjiang Biopharmaceutical Base Development Co., Ltd., holds more than 5% of Yinos's shares but is not a controlling shareholder or a member of the company's board or senior management [5][6]. - The seller has confirmed that the shares are free from any restrictions or prohibitions on transfer and that they have fulfilled all relevant obligations [6][7]. Group 3: Pricing and Transfer Process - The minimum transfer price will not be lower than 70% of the average trading price over the 20 trading days prior to November 4, 2025 [9][10]. - If the total number of valid subscriptions exceeds the number of shares available for transfer, the pricing will follow a priority system based on price, quantity, and time of submission [10]. Group 4: Investor Eligibility - Eligible investors for this transfer include institutional investors with appropriate pricing capabilities and risk tolerance, such as securities companies, fund management companies, and qualified foreign institutional investors [11]. Group 5: Company Status - Yinos does not face any operational risks that require disclosure under the relevant stock exchange rules, and the share transfer will not lead to a change in control of the company [12].

Core Viewpoint - Yinos (688710.SH) plans to participate in the pre-IPO share transfer inquiry, with the seller being Shanghai Zhangjiang Biopharmaceutical Base Development Co., Ltd. [1] Group 1 - The total number of shares to be transferred by the seller is 4,229,388 shares [1] - The shares represent 3.00% of Yinos' total share capital [1]

证券代码：688710 证券简称：益诺思 公告编号：2025-038 上海益诺思生物技术股份有限公司 股东询价转让计划书 上海张江生物医药基地开发有限公司（以下简称"张江生药基地"或"出让 方"）保证向上海益诺思生物技术股份有限公司（以下简称"公司"或"益诺思"） 提供的信息内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其真实性、 准确性和完整性依法承担法律责任。 出让方委托国泰海通证券股份有限公司（以下简称"国泰海通"）组织实施本 次询价转让。截至 2025 年 10 月 31 日，转让方所持公司股份的数量、比例情况 如下： | 序号 | 拟参与转让股东的名称 | 持股数量（股） | 持股占总股本比例 | | --- | --- | --- | --- | | 1 | 张江生药基地 | 15,250,141 | 10.82% | 注：以上持股比例按 2025 年 10 月 31 日公司总股本 140,979,615 股计算。 （二）关于出让方是否为益诺思控股股东、实际控制人、持股 5%以上的股 东、董事及高级管理人员 本次询价转让的出让方持有益诺思的股份比例超过 5%，非公司控股股东、 实际控制人及其 ...

国泰海通证券股份有限公司 关于上海益诺思生物技术股份有限公司 股东向特定机构投资者询价转让股份 相关资格的核查意见 中国（上海）自由贸易试验区商城路 618 号 1 国泰海通证券股份有限公司（以下简称"国泰海通"）受上海益诺思生物技术 股份有限公司（以下简称"益诺思"或"公司"）股东上海张江生物医药基地开发有 限公司（以下简称"张江生药基地"或"出让方"）委托，组织实施本次益诺思首 发前股东向特定机构投资者询价转让（以下简称"本次询价转让"）。 根据《关于在上海证券交易所设立科创板并试点注册制的实施意见》、《科 创板上市公司持续监管办法（试行）》、《上海证券交易所科创板股票上市规则》、 《上海证券交易所科创板上市公司自律监管指引第 4 号——询价转让和配售 （2025 年 3 月修订）》（以下简称"《询价转让和配售指引》"）等相关规定， 国泰海通对参与本次询价转让股东的相关资格进行核查，并出具本核查意见。 一、本次询价转让的委托 国泰海通收到出让方关于本次询价转让的委托，委托国泰海通组织实施本次 询价转让。 二、关于参与本次询价转让股东相关资格的核查情况 （一）核查过程 根据相关法规要求，国泰海通对出让方的相 ...

Group 1 - The core point of the article is that Yinos (688710.SH) has disclosed a shareholder inquiry transfer plan, indicating a significant movement in its shareholding structure [1] - The shareholder involved in this transfer is Shanghai Zhangjiang Biopharmaceutical Base Development Co., Ltd., which plans to transfer a total of 4.2294 million shares [1] - The shares to be transferred represent 3% of the company's total share capital, highlighting a notable percentage of ownership being divested [1]

Group 1 - The core point of the article is that Yinos (688710.SH) has disclosed a shareholder inquiry transfer plan, indicating a significant movement in its shareholding structure [1] - The shareholder involved in this transfer is Shanghai Zhangjiang Biomedicine Base Development Co., Ltd., which plans to transfer a total of 4.2294 million shares [1] - The shares to be transferred represent 3% of the company's total share capital, highlighting a notable change in ownership [1]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1] Core Insights - The rhythm of innovative drug licensing-out transactions has recovered, with a total of 103 transactions and a total amount of $92.03 billion in the first three quarters of 2025, representing a 77% increase compared to the total amount for 2024 [2] - The research and CXO sectors continue to lead the recovery in the pharmaceutical industry, with significant profit growth in these areas [4] - The medical device bidding market has shown a steady recovery, with a year-on-year growth of 29.8% in the third quarter of 2025 [5] - The self-immune field has seen breakthroughs in overseas licensing, indicating a growing alignment with global R&D trends [6] - The weight loss market is experiencing competitive mergers and acquisitions, highlighting its attractiveness and potential impact on Chinese companies [7] - Trends in respiratory infectious diseases are expected to influence the demand for detection and treatment medications [8] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 1.74 percentage points in the last week, ranking 9th among 31 primary industry indices [21] - In the last month, the pharmaceutical industry underperformed the CSI 300 index by 1.83 percentage points, ranking 24th [25] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical industry index has a current PE (TTM) of 38.80, above the five-year historical average of 31.26 [42] 3. Recent Research Achievements - The report highlights various recent research outputs, including weekly industry reports and insights on innovative drug licensing trends [48] 4. Recent Industry Policies and News - The National Healthcare Security Administration has initiated reforms for immediate settlement of medical insurance funds, aiming for 80% coverage by the end of 2025 [50] - Recent news includes significant breakthroughs in GLP-1 therapies and the approval of new drugs for chronic hepatitis B [51][52] 5. Recommended Companies and Profit Forecasts - The report provides a list of recommended companies with their respective EPS and PE ratios, indicating a positive outlook for several firms in the pharmaceutical sector [10]

Core Viewpoint - The company, Shanghai Yinos Biotechnology Co., Ltd., reported strong financial performance in its third-quarter results, highlighting significant growth in revenue and new orders, indicating a robust market position and operational efficiency [1][2]. Financial Performance - For the first three quarters, the company achieved a revenue of 571 million yuan, with third-quarter revenue reaching 195 million yuan, reflecting a quarter-on-quarter growth of 17.71% [1]. - The new order amount increased by 29.37% year-on-year, with the number of new drug clinical trial applications (IND) and new drug marketing applications (NDA) rising by 30.71% [1]. Order and Contract Growth - The contract amount for new drug applications grew by 23.06% year-on-year, and the total order amount on hand increased by nearly 20% compared to the end of 2024 [1]. Industry Position and Strategy - As a leading player in the CRO industry, the company leverages its technological advantages and comprehensive service offerings to meet high-end market demands, capitalizing on the current high-growth cycle in the global CRO sector [2]. - The company has established a dual-driven model of "market demand + forward-looking research," creating a solid technological barrier in the non-clinical evaluation field, reinforcing its leading position in domestic non-clinical safety evaluations [2]. International Market Expansion - The company is actively expanding into international markets through diverse marketing channels, including partnerships with industry capital and collaboration with upstream and downstream players in the industry, resulting in a significant increase in new orders from overseas markets [2]. Focus on Innovative Drug Development - The company continues to focus on high-potential areas in innovative drug development, particularly in emerging categories such as in vivo CAR-T, small nucleic acids, bispecific/multispecific antibodies, and radioactive drugs, with significant year-on-year growth in contract amounts for these innovative categories [2].

Group 1: Industry Overview - The pharmaceutical and biotechnology industry is entering a new upward cycle, with accelerated overseas orders and strong upward momentum, particularly for companies with strong overseas capabilities in the upstream biological sector [1] - The early-stage CRO (Contract Research Organization) industry is experiencing a significant development opportunity, driven by the historical chance for innovative drugs to expand internationally [1] Group 2: Early-stage CRO - The early-stage CRO industry is seeing a shift towards domestic advantages in quality, efficiency, and cost, as overseas demand for early-stage research increases [1] - The demand for preclinical and safety evaluation orders is gradually recovering, with a recommendation to focus on leading companies such as Yino Science and Zhaoyan New Drug [1] - The supply-demand mismatch for experimental monkeys is expected to persist, leading to stable prices in the short term [1] Group 3: Upstream Biological Products - The domestic biological sector is recovering quickly, with significant growth expected in biological reagents, including culture media and recombinant proteins, driven by the structural recovery from domestic innovative drug exports [2] - The overseas market presents vast opportunities, and domestic brands are favored for their cost-effectiveness, suggesting a focus on companies with overseas capabilities such as Baipusais and Haoyuan Pharmaceutical [2] Group 4: Clinical CRO - The clinical CRO sector is approaching a turning point, with SMO (Site Management Organization) orders showing early signs of recovery [3] - As innovative drug financing improves, the number of clinical projects is expected to increase, leading to a recovery in overall orders [3] - Leading clinical CRO companies such as Tigermed and Nossger are recommended for investment [3] Group 5: CDMO - The CDMO (Contract Development and Manufacturing Organization) sector is showing strong performance, particularly in the peptide and ADC (Antibody-Drug Conjugate) segments, which are expected to maintain high growth rates [4] - New molecular tracks, including small nucleic acids, also present significant long-term development potential [4] - Recommended CDMO leaders include Kelaiying and WuXi AppTec, which are expected to show performance elasticity due to stable small molecule business and rapid growth in new molecular business [4]

Core Viewpoint - The company has reported significant growth in its third-quarter performance, with a focus on enhancing its core business and expanding into international markets, while also undergoing governance changes by eliminating the supervisory board [2][3][26]. Financial Performance - The company's third-quarter revenue increased by 17.71% compared to the previous quarter [2]. - New orders increased by 29.37% year-on-year, with a notable 30.71% growth in new drug clinical trial applications (IND) and new drug marketing applications (NDA) [2]. - The total order amount on hand grew by 19.43% compared to the end of 2024, providing a solid foundation for future operations [2]. Market Expansion - The company has established diverse marketing channels to enhance its international market presence, resulting in a significant increase in new orders from overseas markets [3]. - The focus on innovative drug development includes high-potential areas such as CAR-T, small nucleic acids, and multi-specific antibodies, with substantial growth in contract amounts for these innovative categories [3]. Governance Changes - The company plans to abolish the supervisory board, transferring its responsibilities to the audit committee of the board of directors, in compliance with the new Company Law effective from July 1, 2024 [26][27]. - Amendments to the company's articles of association will reflect this governance change and other necessary updates [28][29].